Regeneron Pharmaceuticals market cap REGN

Share price times shares outstanding: what the whole company sells for, since 2010.

Regeneron Pharmaceuticals is worth $82.9B at the close on Oct 23, 2026, at $805.02 a share.

That is up 35% over the last year and up 21% over five years.

Its highest close in our data was $132.2B in Aug 2024.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$82.9B	$63.9B	$85.9B	+0%
2025	$82.5B	$52.9B	$82.5B	+5%
2024	$78.3B	$77.1B	$132.2B	−18%
2023	$95.7B	$76B	$95.7B	+22%
2022	$78.6B	$62.8B	$83.5B	+16%
2021	$67.9B	$48.3B	$72.7B	+32%
2020	$51.6B	$37.1B	$72.5B	+26%
2019	$41B	$30B	$48B	+4%
2018	$39.2B	$31.4B	$44B	−3%
2017	$40.4B	$36.5B	$55B	+4%
2016	$38.7B	$35.7B	$51.2B	−31%
2015	$56.5B	$41.3B	$60.3B	+34%
2014	$42B	$27B	$43.5B	+53%
2013	$27.5B	$15.6B	$30.5B	+70%
2012	$16.2B	$6B	$17.5B	+223%
2011	$5B	$2.7B	$5.9B	+91%
2010	$2.6B	$1.8B	$2.7B	n/a

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

Company	Market cap
REGNRegeneron Pharmaceuticals	$82.9B
VRTXVertex Pharmaceuticals	$132.8B
ONCBeOne Medicines	$42.9B
ALNYAlnylam Pharmaceuticals	$30B
UTHRUnited Therapeutics	$25.2B
INCYIncyte	$23.5B
EXELExelixis	$16B
NBIXNeurocrine Biosciences	$14.5B
HALOHalozyme Therapeutics	$14.3B
TECHBIO-TECHNE	$11.4B
RGENRepligen	$10B
Peer median	$19.7B